Workflow
icon
Search documents
高盛:美洲技术:半导体反映近线 HDD 优势和 NAND 弱点,预计 3Q24 EPS;对 WDCSTX 保持中性
高盛证券· 2024-10-10 13:39
8 October 2024 | 11:19PM EDT _ Americas Technology: Semiconductors Reflecting Nearline HDD Strength and NAND Weakness Ahead of 3Q24 EPS; Maintain Neutral on WDC/STX We raise estimates for Seagate and lower estimates for Western Digital (WD) ahead of CY3Q24 earnings, as we reflect sustained strength in Nearline HDD demand (i.e. EBs and pricing), more than offset by weakness in NAND pricing in the case of WD. Accordingly, we increase our STX 12-month price target to $110 (up from $107 prior), while we lower o ...
高盛:新兴市场交易员_中国宽松政策扩大广度
高盛证券· 2024-10-10 13:39
_ 9 October 2024 | 6:39PM BST The EM Trader China Easing Adds Breadth n China's easing has triggered a broadening in the EM equity rally. The broad EM equity index was held back until the summer amid weak China activity and an underwhelming policy response, coupled with bouts of global macro volatility. With an improving macro cycle led by Fed easing and the much-needed recent coordinated stimulus announcements from China's policymakers, EM equities have staged an impressive rally, with the MSCI EM index up ...
高盛:Bilibili-升级后投资者反馈 - 关注游戏寿命和长期利润;买入
高盛证券· 2024-10-10 13:39
Investment Rating - The report maintains a "Buy" rating for Bilibili Inc. (BILI) with a 12-month price target of $22.60, indicating a potential downside of 14.6% from the current price of $26.46 [1]. Core Insights - The report emphasizes the sustainability of the game "Sanguo NSLG" and its expected contribution to gaming revenue in Q3 and Q4, alongside the company's capabilities in video and advertising business [1][4]. - Bilibili is expected to achieve a profit margin of 10-15% by 2026, driven by improved business mix and operating leverage from new game contributions [1][12]. - The advertising business is projected to outperform industry peers, with expectations of over 20% year-on-year growth in 4Q24/2025, supported by increased ad load and new advertising formats [6][8]. Summary by Sections Financial Projections - Revenue is forecasted to grow from RMB 22,527.9 million in 2023 to RMB 34,673.7 million by 2026, with EBITDA expected to rise from a loss of RMB 654.7 million in 2023 to RMB 6,315.0 million in 2026 [1][3]. - The normalized gross margin for 2026 is estimated at 39%, with a net margin of 12% anticipated [11][12]. Game Performance - "Sanguo NSLG" is expected to generate over RMB 1 billion in revenue recognition for Q3 2024, with a grossing run-rate of at least RMB 0.4 billion in September [1][4]. - The game is projected to maintain a 30% operating profit margin due to lower channel costs and disciplined marketing expenses [5]. Advertising Business - Bilibili's advertising revenue is expected to grow from RMB 1,669 million in Q1 2024 to RMB 2,358 million in Q4 2024, reflecting a year-on-year growth of 31% [10]. - The company is enhancing its ad technology infrastructure and expanding ad slots, which is anticipated to improve monetization efficiency [6][8]. Valuation - Bilibili is currently trading at a 20X 2026E P/E ratio, which is a premium compared to the China internet average of 15X, justified by its higher growth rate [12]. - The implied 2026E P/E for Bilibili ranges from 16X to 22X in various scenarios, indicating a reasonable valuation compared to historical peaks [12].
高盛:老铺黄金_发掘传统黄金珠宝的奢侈需求;首次买入
高盛证券· 2024-10-10 13:39
7 October 2024 | 8:13PM HKT | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|----------- ...
高盛:中国清洁技术:太阳能盈利能力拐点:七宝能源发展步伐略有改善,其他企业进一步恶化
高盛证券· 2024-10-10 13:39
Investment Rating - The report maintains a "Buy" rating on Daqo and Flat H/Xinyi, while Longi is rated "Neutral" and GCL/Tongwei/TCL Zhonghuan are rated "Sell" [3][8]. Core Insights - The solar industry is experiencing a re-balancing of supply and demand, with upstream prices for Poly and Wafer seeing moderate increases, while downstream prices for Cell and Module are under intense competition, leading to a decline in profitability for these segments [1][11]. - Cash burn trends for covered companies are diverging, with Daqo expected to improve due to lower production and disciplined capital expenditure, while Tongwei and Longi are facing deterioration due to high capital expenditures and decreasing prices [2][5]. - A potential price rebound of 5%-10% across the solar value chain is anticipated by 2025, driven by continued supply cuts [3][8]. Summary by Sections Pricing Trends - In September, spot prices for Poly/Wafer increased by 1%, while Cell/Module prices decreased by 2% and 2% respectively, indicating a mixed pricing environment across the solar value chain [11][31]. - The average cash gross profit margin (GPM) for Poly improved slightly, while other segments like Wafer, Cell, and Module saw further declines [1][5]. Production and Inventory - Production for Poly, Wafer, Cell, and Glass decreased by 4%, 4%, 4%, and 8% respectively, while Module production remained flat [8][9]. - Inventory levels showed a moderate decline for downstream Cell and Module, but increased for Wafer and Glass, indicating ongoing inventory pressure [8][9]. Demand Dynamics - Demand for solar installations in China showed a sequential decline, with August installations down 22% month-over-month but up 3% year-over-year [31]. - Module exports remained flat month-over-month but increased by 23% year-over-year, with strong demand noted in the Middle East and APAC regions [31].
高盛:全球经济分析师_核心商品价格下跌幅度有多大_(Pierdomenico)
高盛证券· 2024-10-10 13:39
9 October 2024 | 12:30AM EDT _ | --- | --- | --- | --- | --- | --- | |----------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | Global Economics Analyst | | | | | | n Core goods have been a key disinflation driver over the past 18 months, but the disinflationary impulse from supply-chain normalisation is mostly behind us. In this Global Economics Analyst we assess how much disinflation core goods will provide going forward. n We see several reasons why global core g ...
高盛:澳大利亚金属和矿业_大宗商品、基本金属和钢铁;纯铁矿估值在近期上涨后有所拉高,预测 9 月至季度产量
高盛证券· 2024-10-10 13:39
Investment Rating - The report maintains a "Buy" rating on BHP, RIO, S32, CRN, CIA, DRR, LYC, and BSL, while holding a "Sell" rating on FMG and NHC [3][6]. Core Insights - The recent rally in the mining sector, driven by China stimulus, may fade due to weak demand in developed markets and a shift in China's focus towards property inventory destocking rather than construction [1][2]. - Iron ore is viewed as overvalued at approximately US$110 per ton, while met coal is favored at around US$200 per ton due to strong demand from India [2]. - Base metals, particularly copper, aluminum, and alumina, are preferred over the medium term, while battery materials are viewed negatively for the next 12-24 months [2]. Summary by Sections Market Overview - The mining sector experienced a significant rally, with the second-largest weekly increase in CFTC funds in about 15 years, but this momentum is expected to wane [1]. - Feedback from investor meetings indicates that while there may be short-term positive momentum, many investors are looking to fade the rally in the December quarter [1]. Commodity Price Forecasts - The report adjusts forecasts for various commodities, reducing base metal, steel, and met coal price expectations while upgrading alumina and thermal coal [4][8]. - Specific price forecasts include: - Iron ore (62% Fe) at US$108 per ton for 2023, declining to US$85 by Q4 2024 [8]. - Copper prices are projected to be around US$4.51 per pound in 2022, decreasing to US$4.00 in 2023 [8]. Company Valuations - Pure-play iron ore stocks are considered fully valued, with FMG trading at approximately 7.5x NTM EV/EBITDA and MIN at around 11x, which is a premium compared to major diversified miners [3]. - The report highlights the need for a sustained increase in developed market industrial production and construction activity to support a fundamental re-rating of metal prices in 2025 [2].
高盛:中国半导体_威尔半导体_SG Micro_Kingsemi_Starpower 环比增长;2H24 受产品扩张和更健康的库存支持
高盛证券· 2024-10-10 13:39
Investment Ratings - The report maintains a "Buy" rating on Will Semi and SG Micro, while assigning a "Neutral" rating to Kingsemi and Starpower [1][3][10][16][22]. Core Insights - The semiconductor industry in China is expected to see revenue growth of 12%-55% QoQ in 3Q24, driven by product expansions and improved demand following inventory corrections [1]. - Will Semi is projected to achieve a 25% YoY revenue growth to Rmb7.8 billion in 3Q24, supported by its penetration in the mid-high end smartphone CIS market and automotive applications [3]. - SG Micro is expected to sustain a 33% YoY revenue growth to Rmb978 million in 3Q24, benefiting from diversified product offerings and increasing domestic demand [10]. - Kingsemi anticipates a 29% YoY revenue growth to Rmb658 million in 3Q24, with new orders growing significantly [16]. - Starpower's revenues are expected to grow 21% YoY to Rmb1.1 billion in 3Q24, aided by a recovery in automotive IGBT shipments [22]. Summary by Company Will Semi - Revenue is expected to grow 25% YoY to Rmb7.8 billion in 3Q24, with a net income growth of 31% QoQ to Rmb1.1 billion [3]. - Earnings revisions for 2024-2027 show a 1%-2% increase due to better revenue outlook and product mix upgrades [3][5]. - The 12-month target price is raised to Rmb152.3 based on a 35X 2025 PE [5][9]. SG Micro - Projected 3Q24 revenue growth of 33% YoY to Rmb978 million, with a resilient performance amid industry downturn [10]. - Earnings revisions for 2024-2027 indicate a 1%-11% increase due to improved long-term revenue growth outlook [11][12]. - The 12-month target price is raised to Rmb117.6 based on a 55X 2025 PE [14][15]. Kingsemi - Expected revenue growth of 29% YoY to Rmb658 million in 3Q24, with significant new orders [16]. - Earnings revisions for 2024-2027 show a 1%-7% increase due to better revenue and gross margin outlook [16][17]. - The 12-month target price is raised to Rmb78.6 based on a 33X 2025 PE [17][21]. Starpower - Anticipated revenue growth of 21% YoY to Rmb1.1 billion in 3Q24, supported by automotive IGBT shipments [22]. - Earnings revisions for 2024 show an 18% decrease due to a 2Q earnings miss, but a 1%-2% increase for 2025-2027 [22][24]. - The 12-month target price is raised to Rmb101.5 based on a 19X 2025 PE [24][27].
高盛:石药集团_与跨国公司达成的首个海外 BD 交易;授权代谢药物.
高盛证券· 2024-10-10 13:39
Investment Rating - The investment rating for CSPC Pharma is "Buy" with a 12-month price target of HK$10.03, representing an upside of 40.9% from the current price of HK$7.12 [5][6][11]. Core Insights - CSPC Pharma has entered into its first overseas business development deal by licensing a pre-clinical metabolism drug, YS2302018, to AstraZeneca for an upfront payment of US$100 million, potential development milestone payments of up to US$370 million, sales milestone payments of up to US$1,550 million, and tiered royalties based on net sales [1][2]. - This collaboration is seen as a significant step for CSPC's global expansion and validates its early-stage innovative pipeline, which is not yet reflected in its current valuation [1][2]. - CSPC aims to close 1-2 more business development deals by the end of 2024, indicating a proactive approach to enhancing its pipeline under new R&D leadership [1]. Summary by Sections Licensing Deal - CSPC has licensed out YS2302018, a small molecule inhibitor targeting lipoprotein(a), to AstraZeneca, marking a strategic collaboration that could enhance CSPC's global presence [1][2]. - The deal includes an upfront payment of US$100 million, which is significant for a pre-clinical asset, along with potential milestone payments totaling up to US$2.42 billion [1]. Product Potential - YS2302018 is positioned as a differentiated oral TKI targeting lipoprotein(a), which is linked to cardiovascular diseases, with a high prevalence in older populations [2]. - The drug's oral administration is a competitive advantage over existing therapies that require injections, making it more suitable for chronic disease management [2]. Financial Projections - CSPC's revenue projections for the upcoming years are Rmb 31,450.1 million for 2024, increasing to Rmb 38,080.8 million by 2026, with corresponding EBITDA growth [5]. - The company is expected to maintain a P/E ratio that decreases from 13.0 in 2024 to 10.1 by 2026, indicating improving profitability [5].
高盛:中国光模块第三季度预览;持续的需求强劲;供应动态值得关注
高盛证券· 2024-10-10 13:39
Investment Rating - The report maintains a "Buy" rating on Innolight, Eoptolink, and HG Tech, while assigning a "Neutral" rating to TFC Optical [1][18][21][24]. Core Insights - The optical transceiver sector is expected to experience strong growth driven by robust demand from AI networking, with supply dynamics being a critical factor to monitor [1][5]. - The report anticipates strong year-over-year and quarter-over-quarter profit growth for the companies covered in the upcoming earnings season, with a focus on supply dynamics, particularly upstream laser component supplies [1][4]. - The report highlights the potential for silicon photonics adoption as a response to tight 100G EML supplies, which could benefit Innolight due to its early mover advantage [5][6]. Summary by Company Innolight - Revenue for 3Q24 is estimated at RMB 6,837 million, reflecting a 126% year-over-year increase and a 15% quarter-over-quarter increase [4]. - The 12-month price target is revised to RMB 230 based on a 26x 2025E P/E, indicating an upside of 48.5% [13][18]. Eoptolink - Revenue for 3Q24 is projected at RMB 2,215 million, showing a 183% year-over-year increase and a 37% quarter-over-quarter increase [4]. - The 12-month price target is revised to RMB 180 based on a 27x 2025E P/E, with an upside of 38.5% [15][21]. HG Tech - Revenue for 3Q24 is expected to be RMB 3,609 million, a 65% year-over-year increase and a 19% quarter-over-quarter increase [4]. - The 12-month price target is revised to RMB 52 based on a 26x 2025E P/E, indicating an upside of 48.9% [22][24]. TFC Optical - Revenue for 3Q24 is estimated at RMB 947 million, reflecting a 75% year-over-year increase and a 15% quarter-over-quarter increase [4]. - The 12-month price target is revised to RMB 112 based on a 30x 2025E P/E, with an upside of 11.4% [27][28].